BPG致力于知识发现和传播
Articles Published Processes
2025/9/28 13:26:57 | Browse: 5 | 下载: 7
| Publication Name |
世界华人消化杂志 |
| 手稿编号 |
40344 |
| 手稿来源省、自治区或特别行政区 |
浙江省 |
 |
Received |
|
2025-07-24 03:15 |
|
Peer-Review Started |
|
2025-07-24 03:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-08-21 00:54 |
|
修回稿 |
|
2025-09-04 15:24 |
|
Second Decision |
|
2025-09-15 10:20 |
|
期刊总编辑接受 |
|
|
|
公司总编辑接受 |
|
2025-09-17 08:04 |
|
预出版 |
|
2025-09-17 08:04 |
|
缴纳版面费 |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
排版 |
|
2025-09-27 07:51 |
|
在线出版 |
|
2025-09-28 13:26 |
| ISSN |
1009-3079 (print) and 2219-2859 (online) |
| 开放获取 |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| 版权 |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| 网址 |
http://www.wjgnet.com |
| 专业类型 |
消化内科学 |
| 手稿栏目类型 |
临床研究 |
| 文章标题 |
阿帕替尼通过VEGFR2-PLC-ERK1/2通路抑制结肠癌LS174T细胞增殖的机制研究
|
| 手稿来源 |
自由来稿 |
| 所有作者列表 |
崔亦筱, 余德顺, 张诗琪 |
| ORCID |
|
| 基金项目及其编号 |
|
| 通讯作者 |
崔亦筱, 本科, 主治医师, 310000, 浙江省杭州市拱墅区东新路848号, 树兰（杭州）医院药剂科. songjing79196567@163.com |
| 关键词 |
结肠癌; 阿帕替尼; 细胞凋亡; 细胞周期; VEGFR2-PLC-ERK1/2通路 |
| 核心内容提要 |
结肠癌(colorectal cancer, CRC)治疗中, 血管内皮生长因子/血管内皮生长因子受体[(vascular endothelial growth factor, VEGF)/(vascular endothelial growth factor receptor, VEGFR)]靶向药物是研究重点. 阿帕替尼作为小分子酪氨酸激酶抑制剂, 通过特异性结合VEGFR-2, 抑制VEGF诱导的内皮细胞增殖及微血管生成. 其机制涉及阻断VEGFR2-PLC-ERK1/2信号通路, 进而抑制肿瘤血管形成和CRC细胞增殖. 体外及裸鼠移植实验证实, 阿帕替尼对胃癌、CRC等实体瘤具有显著抗肿瘤活性, 为晚期CRC治疗提供了新策略. |
| 出版日期 |
2025-09-28 13:26 |
| 引文著录 |
崔亦筱, 余德顺, 张诗琪. 阿帕替尼通过VEGFR2-PLC-ERK1/2通路抑制结肠癌LS174T细胞增殖的机制研究. 世界华人消化杂志 2025; 33(9): 741-748 |
| URL |
https://www.wjgnet.com/1009-3079/full/v33/i9/741.htm |
| DOI |
https://dx.doi.org/10.11569/wcjd.v33.i9.741 |
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
